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age of the patients was 59 years in the LMWH group and 58.2 years in OA group.
Study design
This was a prospective randomised controlled trial that was carried out at a single centre. Randomisation was performed using a computer. The patients were followed up at 4 weeks and 3, 6 and 12 months after discharge. No patient was lost to the follow-up assessment.
Analysis of effectiveness
It appears that all the patients included in the initial study have been accounted for in the clinical analysis. The primary outcomes used were the reduction in quantitative ultrasonographic score and the vein reflux score. The secondary outcomes were the incidence of major and minor haemorrhagic complications, mortality, and the incidence of recurrent DVT and PE. The study groups were well balanced in terms of the patient demographics and baseline characteristics.
Effectiveness results
The LMWH group produced a significantly lower Marder score than the OA group from 3 months onwards. In the LMWH group versus the OA group, the median Marder scores were 9 (range: 7 -10) versus 10 (range: 8 -15), (p=0.017) at 3 months, 6.5 (range: 4 -9) versus 8 (range: 6 -12), (p=0.013) at 6 months, and 5 (range: 3 -7) versus 7 (range: 5 -10), (p=0.011) at 12 months.
When patients were divided into sub-groups, thrombus regression was significantly in favour of tinzaparin for the following sub-group and times.
For common femoral vein, the median Marder scores in the LMWH versus OA group were 1 (range: 1 -3) versus 2 (range: 2 -3), (p=0.025) at 6 months, and 1 (range: 1 -2.25) versus 2 (range: 2 -3), (p=0.008) at 12 months.
For superficial femoral vein, the median Marder scores in the LMWH versus OA group were 4 (range: 2 -6) versus 5 (range: 3.25 -6), (p=0.035) at 3 months, 3 (range: 2 -5) versus 5 (range: 3 -6), (p=0.013) at 6 months, and 13 (range: 2 -5) versus 4 (range: 3 -5.25), (p=0.032) at 12 months.
For popliteal vein, the median Marder scores in the LMWH versus OA group were 2 (range: 2 -3) versus 3 (range: 2 -4), (p=0.021) at 3 months, 2 (range: 1 -3) versus 2 (range: 2 -3), (p=0.027) at 6 months, and 1 (range: 1 -2) versus 2 (range: 1 -3), (p=0.018) at 12 months.
The mean scores were also presented.
The overall incidence of major events was 14% in the LMWH group and 32.7% in the OA group, (p=0.0354).
Only those results achieving statistical significance have been reported here. Full results were presented in the paper.
Clinical conclusions
The effectiveness study showed that treatment with tinzaparin was at least as effective and safe as that of UFH and acenocoumarol. In terms of major events and recanalisation, there was a significant benefit in favour of tinzaparin.
Measure of benefits used in the economic analysis
No summary measure of health benefits was used in the economic analysis. In effect, a cost-consequences analysis was performed.
Direct costs
This economic study adopted the cost/quantity boundary of a health care system. The costs of hospitalisation, laboratory tests and drug therapy were included in the economic analysis. The costs of tests performed equally in both groups were excluded from the study. The unit costs were reported separately from the quantities of resources used. The cost data were obtained from hospital charges. No cost-to-charge ratio appears to have been used. The source of the costs and resources used was unclear. Discounting was not reported as it was irrelevant. The price year was not reported.
Statistical analysis of costs
A statistical analysis was performed to test the significance of differences in the estimated costs.
Indirect Costs
In line with the stated perspective, the indirect costs were not included in this analysis.
Currency
Euros (Euro).
Sensitivity analysis
Sensitivity analyses were not performed.
Estimated benefits used in the economic analysis
See the 'Effectiveness Results' section.
Cost results
The total costs in the LMWH group (Euro 2,432.7) were slightly lower than those in the OA group (Euro 2,504.56).
Synthesis of costs and benefits
A synthesis of the costs and benefits was not relevant.
Authors' conclusions
Based on clinical and economic evidence, the long-term treatment of deep venous thrombosis (DVT) with tinzaparin could be an appropriate alternative to conventional treatment.
CRD COMMENTARY -Selection of comparators
The justification for the choice of the comparator was clear. UFH followed by OAs in DVT represented the traditional practice. You should decide whether this is a valid comparator in your own setting.
Validity of estimate of measure of effectiveness
The effective evidence was derived from a prospective, randomised controlled trial. This was appropriate for the study question as it provided a robust assessment of the clinical implications of the two treatment approaches. The study groups were shown to be comparable at baseline. The patients were identified at a single centre, which may reduce the transferability of the results to other settings. Power calculations were not used to decide the sample size, which means that the possibility that the study lacked sufficient power to obtain significant results cannot be ruled out.
